ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer

  • Shuai Gao
    1Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
  • Huihui Ye
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Sean Gerrin
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Hongyun Wang
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Ankur Sharma
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Sen Chen
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Akash Patnaik
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Adam G. Sowalsky
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Olga Voznesensky
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Wanting Han
    1Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.
  • Ziyang Yu
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Elahe A. Mostaghel
    4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.
  • Peter S. Nelson
    4Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.
  • Mary-Ellen Taplin
    5Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Steven P. Balk
    2Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Changmeng Cai
    1Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts.

抄録

<jats:title>Abstract</jats:title> <jats:p>Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor (AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but agents targeting ErbB2 have not been effective. This study was undertaken to assess ErbB2 activity in abiraterone-resistant prostate cancer and to determine whether it may contribute to AR signaling in these tumors.</jats:p> <jats:p>Experimental Design: AR activity and ErbB2 signaling were examined in the radical prostatectomy specimens from a neoadjuvant clinical trial of leuprolide plus abiraterone and in the specimens from abiraterone-resistant CRPC xenograft models. The effect of ErbB2 signaling on AR activity was determined in two CRPC cell lines. Moreover, the effect of combination treatment with abiraterone and an ErbB2 inhibitor was assessed in a CRPC xenograft model.</jats:p> <jats:p>Results: We found that ErbB2 signaling was elevated in residual tumor following abiraterone treatment in a subset of patients and was associated with higher nuclear AR expression. In xenograft models, we similarly demonstrated that ErbB2 signaling was increased and associated with AR reactivation in abiraterone-resistant tumors. Mechanistically, we show that ErbB2 signaling and subsequent activation of the PI3K/AKT signaling stabilizes AR protein. Furthermore, concomitantly treating CRPC cells with abiraterone and an ErbB2 inhibitor, lapatinib, blocked AR reactivation and suppressed tumor progression.</jats:p> <jats:p>Conclusions: ErbB2 signaling is elevated in a subset of patients with abiraterone-resistant prostate cancer and stabilizes AR protein. Combination therapy with abiraterone and ErbB2 antagonists may be effective for treating the subset of CRPC with elevated ErbB2 activity. Clin Cancer Res; 22(14); 3672–82. ©2016 AACR.</jats:p>

収録刊行物

  • Clinical Cancer Research

    Clinical Cancer Research 22 (14), 3672-3682, 2016-07-14

    American Association for Cancer Research (AACR)

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ